A) demethylase fat mass and obesity-associated protein (FTO) in the regulation of chemo-radiotherapy resistance remains largely unknown. Here, we show that the mRNA level of FTO is elevated in cervical squamous cell carcinoma (CSCC) tissues when compared with respective adjacent normal tissues.
The role of N 6 -methyladenosine (m 6 A) demethylase fat mass and obesity-associated protein (FTO) in the regulation of chemo-radiotherapy resistance remains largely unknown. Here, we show that the mRNA level of FTO is elevated in cervical squamous cell carcinoma (CSCC) tissues when compared with respective adjacent normal tissues.
FTO enhances the chemo-radiotherapy resistance both in vitro and in vivo through regulating expression of β-catenin by reducing m 6 A levels in its mRNA transcripts and in turn increases excision repair cross-complementation group 1 (ERCC1) activity.
Clinically, the prognostic value of FTO for overall survival is found to be dependent on β-catenin expression in human CSCC samples. Taken together, these findings uncover a critical function for FTO and its substrate m 6 A in the regulation of chemoradiotherapy resistance, which may bear potential clinical implications for CSCC treatment.
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| INTRODUCTION
Cervical cancer is one of the most common and devastating gynecologic malignancies, especially in the developing world. Over 90% of cervical cancers are squamous cell carcinoma. 1 Chemoradiotherapy is the main component of cervical squamous cell carcinoma (CSCC) management. [2] [3] [4] However, primary or obtained chemo-radiotherapy resistance leads to the treatment failure.
Therefore, understanding of the molecular mechanisms for chemoradiotherapy resistance in CSCC and exploring new target therapies to overcome the resistance are urgently needed. 5, 6 N 6 -methyladenosine (m 6 A) is one of the most prevalent modifications of messenger RNA (mRNA) in mammalian. 7, 8 Recent studies indicate that m 6 A modification involves in various aspects of the mRNA processing regulation, including alternative splicing, 9 RNA degradation and translation, 10 as well as microRNA processing. 11 It is well known that m 6 A modification is catalyzed by a methyltransferase
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complex consisting of "writers" proteins methyltransferase-like 3 (METTL3) and METTL4, 12 and "erasers" fat mass and obesityassociated protein (FTO) and AlkB homolog 5 (ALKBH5). 13, 14 Alternation of these component genes in the methyltransferase complex can give rise to a significant phenotype change, such as carcinogenesis. [15] [16] [17] [18] [19] [20] [21] FTO, the first identified "eraser" of m 6 A, has been reported to play an oncogenic role in various types of cancer, including endometrial, 22 breast, 23 pancreatic cancer, 24 and acute myeloid leukemia (AML), 25 suggesting the functional importance of the mRNA m 6 A methylation and its modulators in cancer. Nonetheless, FTO or m 6 A methylation profiles and functions in the regulation of chemo-radiotherapy resistance have rarely been investigated and prompted us to investigate the role and underlying mechanisms of the FTO or m 6 A in CSCC chemo-radiotherapy resistance regulation.
In this study, we found that FTO overexpression increased chemoradiotherapy resistance of CSCC both in vitro and in vivo. We also showed that FTO-induced upregulation of β-catenin via mRNA demethylation and subsequently activation of excision repair crosscomplementation group 1 (ERCC1) contributed to the resistance.
Furthermore, our data demonstrated the prognostic role of FTO and β-catenin expression in human CSCC. These findings revealed an important molecular mechanism how FTO contributed to chemoradiotherapy resistance and to poor prognosis of CSCC. As we know, supplemented with 10% fetal bovine serum and maintained at 37°C in an atmosphere of 5% CO 2 and 95% room air.
| Lentiviral transduction for stable cell lines
For FTO overexpression, CSCC cells were transduced by using the lentivirus and 50 µg/mL polybrene (Sigma, St. Louis, MO) for 72 h.
After the transduction, cells were selected with 2 mg/mL puromycin for 48 h. Cells stably overexpressing FTO were checked by qRT-PCR 
| Irradiation
Irradiation was carried out using a linear accelerator (Varian, Palo Alto, CA) at a dose rate of 300 MU/min in General Hospital of Ningxia Medical University. The doses applied in the in vitro experiments varied from 0 to 6 Gy. For in vivo experiments, a total of 8 Gy irradiation was delivered using parallel-opposed beams one time.
| MTT assay
Cells were seeded in 96-well plates at a density of 1 × 10 3 per well.
After treated with varying concentrations of cisplatin (Sigma) (0-100 µM) and 2 Gy irradiation for 24 h, cells were incubated with 5 mg/mL MTT (10 µL/well). After 4 h incubation, 100 µL dimethyl sulfoxide (DMSO) was added each well to terminate the reaction. The absorption value at 450 nm was measured to calculate the relative viable cells. The experiment was repeated at least three times.
| Colony formation assay
Cells were seeded in 6-well plates at densities of 1 × 10 
| qRT-PCR
The total RNA was isolated from CSCC cell lines and patient samples 
| IHC analysis
IHC was performed on 4 µM thickness formalin-fixed paraffinembedded tissue from either xenografts or CSCC patient's specimens.
Antigen retrieval was performed in microwave oven with ethylene diamine tetraacetic acid (EDTA) (pH 8.0) before incubation with a primary antibody. After blocking with goat serum, the slides were incubated with indicated antibody overnight at 4°C. The immunolabeled slides were visualized with 3,3′-diaminobenzidine and counterstained with hematoxylin. Finally, the stained slides were independently analyzed by different pathologists using a semiquantitative method as previously described. 26 The following antibodies were used for IHC staining: FTO, Ki-67, cleaved caspase 3, and β-catenin (Abcam). A antibody wasdone as previously described. 18, 21 The m 6 A+ β-catenin mRNA level was finally determined by qRT-PCR using following primers: β-catenin, 5′-CAGGGA-GAACCCCTTGGATA-3′ and 5′-GTTCCATCATGGGGTCCATA-3′. 3 | RESULTS
| Statistical analysis
| FTO expression is elevated in CSCC tissue
To understand the relevance of FTO in CSCC development, we compared the expression pattern of FTO between different tissues. As shown in Figure 1A , an upregulation of FTO in high grade cervical squamous intraepithelial neoplasia compared with normal cervical tissue was observed in GSE7803 database. In addition, we also evaluated the different expression levels of FTO between cervical cancer tissue and normal cervical tissue from the GSE9750 database, and confirmed that the expression levels of FTO were elevated in CSCC tissue with marginal statistically significance ( Figure 1B ). FTO expression levels were also compared between poorly differentiated CSCC and adjacent normal cervical tissue on samples from our own cohort by qRT-PCR and elevated FTO expression levels were observed in poorly differentiated CSCC tissue ( Figure 1C ). These results indicate the correlation of FTO expression and the invasiveness of CSCC.
| FTO promotes chemo-radiotherapy resistance of CSCC in vitro and in vivo
In consideration of the FTO overexpression in CSCC and its critical role in mRNA demethylation, we hypothesized that FTO could regulate the chemo-radiotherapy sensitivity of human CSCC. To test the hypothesis, we first forced the FTO expression in two CSCC cell lines, SiHa and c-33a cells. FTO mRNA and protein upregulation was confirmed using
qRT-PCR and Western blotting (Figure 2A ). After that, we treated FTO FIGURE 1 Expression of fat mass and obesity-associated protein (FTO) between different cervical tissues. The different FTO mRNA levels between normal cervical and high grade cervical squamous intraepithelial neoplasia tissue (A), between normal cervical tissue and cervical squamous cell carcinoma (CSCC) (B) of the GEO databases. Differential expression of FTO between normal cervical tissue and poorly differentiated CSCC tissue was explored in our cohort using qRT-PCR analysis (C). The GEO databases were accessed using the Oncomine database (www.oncomine.com). N = sample number. FTO expression levels are shown as box plots and the vertical bars representing the range of data. P values were obtained using Student's t-test to compare FTO expression between two different groups FIGURE 2 FTO overexpression is associated with chemo-radiotherapy resistance of CSCC in vitro and in vivo. FTO overexpression was confirmed at mRNA and protein level by qRT-PCR and Western blotting in both SiHa and c-33a cell lines (A). FTO confers the chemoradiotherapy resistance of CSCC in vitro. Chemo-radiotherapy sensitivity of wide-type and FTO overexpressed SiHa and c-33a cell lines was assessed using MTT (B) and colony-formation assay (C). SiHa cells was treated with the FTO inhibitor MA2 (40 µM) and chemo-radiotherapy therapy as indicated in (B) and (C). The increased chemo-radiotherapy sensitivity after FTO inhibition of SiHa cells was shown in MTT and clonogenic survival assay (D). FTO confers the chemo-radiotherapy resistance of CSCC in vivo. The xenograft model was established using wide-type and FTO overexpressed SiHa cells. FTO overexpression significantly increased the chemo-radiotherapy resistance compared with wide-type group (P < 0.05) (E). FTO (P < 0.01), ki-67 (P < 0.05), and cleaved caspase3 (P < 0.05) expression was assessed by immunohistochemistry (IHC) from xenograft tumors (N = 6 for each group) harvested at the end of the experiment. All experiments were repeated at least three times with error bars representing ± SEM. Asterisks indicate statistical significance (*P < 0.05, **P < 0.01, and ***P < 0.001) were obtained using two-way ANOVA ZHOU ET AL. Consistent with the in vitro data, FTO overexpression increased the chemo-radiotherapy resistance of CSCC xenograft ( Figure 2E ). IHC staining demonstrated that FTO forced both the expression of ki-67 and cleaved caspase3 ( Figure 2F ).
Collectively, these results confirm that FTO promotes the chemoradiotherapy resistance of CSCC.
| FTO confers chemo-radiotherapy resistance of CSCC by targeting β-catenin through mRNA demethylation
Increased evidences suggest that EMT involves in the resistance of anticancer treatments. 28 SiHa cells ( Figure 3B ).
Next, we investigated whether the inhibition of β-catenin could rescue the FTO promoted chemo-radiotherapy resistance in CSCC cells. We knocked down β-catenin in both SiHa and FTO overexpressed SiHa cells ( Figure 3C ) and tested the chemo-radiotherapy 
| ERCC1 contributes to FTO/β-catenin induced chemo-radiotherapy resistance in CSCC
The downstream modulators of FTO upregulated β-catenin, which contributed to chemo-radiotherapy resistance of CSCC, were also evaluated in current study. First, we screened the markers of Wnt/β-catenin pathway. The results showed that canonical Wnt/β-catenin pathway did not involve in the FTO upregulated β-catenin ( Figure S1 ).
In our previous study, 32 we found ERCC1, an important regulator of 
| The prognostic value of FTO and β-catenin in CSCC patient
To determine the prognostic value of FTO and β-catenin in clinic, we analyzed FTO and β-catenin expression of patients with CSCC treated with surgery and postoperative chemo-radiotherapy at our hospital using IHC and determined their relationship with overall survival (OS) (patient characteristics in Table S1 ). The percentage of patients received postoperative chemo-radiotherapy was 55.9%. Results
showed that the expression of FTO and β-catenin was significantly higher in CSCC tissue compared with the adjacent normal tissue ( Figure 4B) . A positive correlation between the expression level of FTO and its target β-catenin was also observed in our cohort. The correlation coefficient of these two factors was 0.493 (P < 0.001).
Results of Kaplan-Meier analysis indicated that the expression of FTO was not associated with the 5-year OS, which was 87.5% in the FTO negative group compared to 90.5% in the FTO positive group (P = 0.595; Figure 4C ). However, CSCC patients with high expression of both FTO and β-catenin had a poorer prognosis than those with low FTO or β-catenin expression (P = 0.041; Figure 4C ). These results
FIGURE 4
The prognostic value of FTO is dependent on β-catenin localization. The effect of forced expression of FTO and knocking down of β-catenin on excision repair cross-complementation group 1 (ERCC1) was determined by Western blotting analysis (A). Representative IHC staining of FTO and β-catenin in human CSCC patient's specimens (B). Kaplan-Meier survival curve of CSCC patients with "High FTO" or "Low FTO" (upper) and with "High FTO and β-catenin" or "the other" (lower) (C). Proposed model of FTO regulated β-catenin mRNA demethylation and role in human CSCC chemo-radiotherapy resistance regulation. The P values were obtained using Log-rank test confirm the clinical value and correlation of FTO and β-catenin in CSCC patient.
| DISCUSSION
In this study, we demonstrated that FTO contributed to the regulation Figure 4D .
RNA epigenetics has become an interesting field of cancer research recently. The m 6 A modification is one of the most common and critical mRNA modifications in human malignant diseases. 7, 8 More and more evidences suggest that the "writers," "erasers," and "readers" of m 6 A exert important role in the cancer initiation and development. [15] [16] [17] [18] [19] [20] [21] As the first identified "erasers" of m 6 A, FTO was showed associated with not only the increased body mass and obesity 33 but also the progression of various types of cancer.
Previously, the relationship between FTO and cancer was mostly 
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